ACRS - Aclaris Lilly ink patent license deal for Olumiant to treat alopecia areata

• Aclaris Therapeutics ( NASDAQ: ACRS ) signed a non-exclusive patent license agreement with Eli Lilly ( LLY ) for baricitinib to treat alopecia areata, a hair loss disorder.
• Under the agreement, Aclaris granted Lilly non-exclusive rights under certain patents and patent applications which  Aclaris exclusively licenses from The Trustees of Columbia University in the City of New York, for using baricitinib to treat alopecia areata.
• Financial terms were not disclosed but the agreement includes an upfront payment, regulatory and commercial milestones and royalties.
• Lilly ( LLY ) and Incyte ( INCY ) received approval for Olumiant, also known as baricitinib, in the U.S. to treat alopecia areata. The drug has also shown efficacy in reducing the risk of death in certain patients with COVID-19.

For further details see: